Development of a Multiscale Mechanistic Model for Predicting Tumor Response to Anti-miR-155

In this paper, we present a two-compartmental multiscale mechanistic model for investigating anti-miR-155 monotherapy for non-small cell lung cancer (NSCLC). The model was first quantified using in vivo data and subsequently extrapolated to human-scale for evaluating its translational potential in patients. Using the human-scale model, we explored the impact of dosing schedules on tumor response. The model demonstrated the efficacy of anti-miR-155 monotherapy in a virtual NSCLC patient, revealing treatment schedule-dependent suppression of tumor growth. Further analysis of the model will include testing the synergistic effects of anti-miR-155 with standard-of-care drugs, which will help design and optimize treatment schedules for combination therapy in NSCLC.